Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Issue 3 (September 2015)

• Record Type: Journal Article
• Authors: Kossai, M.; Duchemann, B.; Boutros, C.; Caramella, C.; Hollebecque, A.; Angevin, E.; Gazzah, A.; Bahleda, R.; Ileana, E.; Massard, C.; Vielh, P.; Soria, J.C.; Besse, B.
• Is Part Of: Lung cancer. Volume 89:Issue 3(2015:Sep.)
• Page Start: 306
• Page End: 310
• Publication Date: 2015-09
• Subjects: Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.06.014
• Languages: English
• ISSNs: 0169-5002

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Thymic malignancies represent a rare disease associated with poor prognosis.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">When refractory at standard treatments, only few therapeutic options are available.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Herein are the outcomes of 22 patients with advanced disease, in Phase I trials.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">The use of mTOR inhibitors and anti-angiogenic agents showed promising results.</p> </list-item> </list> </p> </sec> </abstract>